|
Real-time Estimate
Tradegate
12:35:36 21/08/26 am AEST
|
5-day change | 1st Jan Change | ||
| 0.7510 EUR | +0.81% |
|
+0.40% | +428.17% |
| 17/08 | Valerio Therapeutics Nears Final Deal for Etherna Immunotherapies Purchase | MT |
| 16/07 | Valerio Therapeutics, Abivax Enter R&D Collaboration for Inflammatory Disease Therapies | MT |
Company Valuation: Valerio Therapeutics
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 52.01 | 38.52 | 15.64 | 25.42 | 11.55 | 67.46 |
| Change | - | -25.93% | -59.41% | 62.58% | -54.58% | 484.18% |
| Enterprise Value (EV) 1 | 43.74 | 30.57 | 11.19 | 29.61 | 26.93 | 74.72 |
| Change | - | -30.12% | -63.41% | 164.7% | -9.03% | 177.44% |
| P/E | 66.7x | -6x | -0.76x | -1.1x | -0.47x | -6.9x |
| PBR | 1.79x | 1.17x | 0.7x | 1.72x | -1.29x | 33.2x |
| PEG | - | 0x | -0x | 0.1x | -0.07x | 0.1x |
| Capitalization / Revenue | 29.3x | 9.48x | 10.8x | 14.1x | 6.44x | 26.2x |
| EV / Revenue | 24.6x | 7.53x | 7.75x | 16.4x | 15x | 29x |
| EV / EBITDA | -5.69x | -5.52x | -0.66x | -1.57x | -6.91x | 21.7x |
| EV / EBIT | -5.6x | -5.48x | -0.65x | -1.55x | -1.63x | -136x |
| EV / FCF | -4.87x | -4.16x | -3.83x | -3.02x | 4.67x | -101x |
| FCF Yield | -20.5% | -24.1% | -26.1% | -33.1% | 21.4% | -0.99% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.01 | -0.07 | -0.185 | -0.1505 | -0.16 | -0.02 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 1.776 | 4.062 | 1.443 | 1.8 | 1.793 | 2.573 |
| EBITDA 1 | -7.69 | -5.535 | -17.04 | -18.92 | -3.896 | 3.45 |
| EBIT 1 | -7.814 | -5.582 | -17.11 | -19.05 | -16.49 | -0.55 |
| Net income 1 | 1.089 | -5.937 | -19.56 | -20.34 | -23.93 | -4.898 |
| Net Debt 1 | -8.266 | -7.953 | -4.452 | 4.184 | 15.38 | 7.26 |
| Reference price 2 | 0.6670 | 0.4200 | 0.1408 | 0.1650 | 0.0750 | 0.1380 |
| Nbr of stocks (in thousands) | 77,977 | 91,722 | 111,059 | 154,077 | 153,972 | 488,848 |
| Announcement Date | 23/4/21 | 28/4/22 | 29/4/23 | 2/5/24 | 9/7/25 | 28/4/26 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 36.57x | 13.2x | 26.79x | 0.54% | 1,141B | |
| 30.41x | - | - | 1.96% | 659B | |
| 33.95x | 7.85x | 16.34x | 2.58% | 470B | |
| 20.47x | 4.85x | 12.03x | 2.72% | 366B | |
| 22.39x | 5.8x | 14.38x | 2.75% | 302B | |
| 21x | 4.33x | 12.29x | 2.03% | 254B | |
| 27.98x | 7.21x | 12.8x | 2.28% | 239B | |
| 13.62x | 4.84x | 10.15x | 3.77% | 207B | |
| -45.1x | 6.51x | 25.42x | 2.23% | 183B | |
| Average | 17.92x | 6.82x | 16.27x | 2.32% | 424.55B | |
| Weighted average by Cap. | 25.80x | 8.63x | 18.95x | 1.88% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALVIO Stock
- C4X Stock
- Valuation Valerio Therapeutics
Select your edition
All financial news and data tailored to specific country editions
